Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and available to Medicare beneficiaries with diabetes who meet eligibility criteria.
Indicated for diabetes management in patients aged four years or older, the updated version of Abbott's system can...
The American Diabetes Association's 80th Scientific Sessions kicked off this weekend, and a handful of diabetes management device-makers and service providers highlighted new data as part of the virtual clinical conference. Read on for summaries of the studies and findings, as well as links to the online abstracts.
Onduo
Verily-backed diabetes management service Onduo, which combines a mobile app...
A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional fingerstick testing.
Abbott’s system uses flash continuous glucose monitoring (CGM) through a sensor placed to the back of the upper arm, and lasts for up to 14 days. The device automatically collects...
Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated Insulin Delivery System which uses a tubeless, wearable “Pod” to deliver insulin for 72 hours at a time.
Abbott and Insulet have partnered to offer a new integrated digital health platform that will...
Bigfoot Biomedical, a diabetes startup looking to automate insulin delivery via a connected insulin pen, has kicked off its Series C round with an initial tranche of $45 million. The raise is headed once again by Abbott, with prior backers Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management pitching in once again.
Alongside the news of its raise, Bigfoot...
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the company shared during an investor’s call this morning.
Specifically, the company highlighted a 72.9% increase in organic sales growth during the three-month period, reaching a worldwide total sales...
On Friday, the American Diabetes Association kicked off its annual conference in San Francisco, where academics, vendors and other stakeholders congregated to unveil new study results and major announcements related to diabetes management. And while MobiHealthNews already put together a roundup featuring an opening salvo of the show’s announcements, the past few days have seen a tidal wave of new...
Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the companies announced this morning.
"Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors," Anders Dyhr Toft, CVP of commercial innovation at Novo...
Correction: A previous version of this article failed to specify that the deal concerns Freestyle Libre Pro, rather than the consumer version, Freestyle Libre.
Livongo Health, the digital chronic disease management company founded by former Allscripts CEO Glen Tullman, announced today that it will be the first United States enterprise diabetes management company to bring Abbott’s Freestyle Libre...
Look to the skies. A recent report by Nesta, a global innovation foundation, conducted in collaboration with five UK cities suggests that no small number of regulatory and infrastructural obstacles stand in the way of medical drone deliveries in the country. While the technology could increase the testing speed and decrease costs for the UK’s National Health Service, the country would need to...
